CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers

CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers

Cyclin-dependent kinases (CDKs) inhibitors have been approved in the combination with hormone-based therapy for advanced breast cancer. In addition to endocrine therapy, the combinations of CDK4/6 inhibitors with epidermal growth factor receptor (EGFR) inhibitors, phosphoinositide 3-kinase (PI3K)/ma...

Full description

Bibliographic Details
Main Authors: ZHANG Baihong, YUE Hongyun
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2019-01-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
neoplasms
therapeutics
cdk4/6 inhibitors
Online Access:http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0906.htm

Similar Items

Similar Items